Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Fig. 3

Mean change (unadjusted) in DAS28-ESR, CDAI, and HAQ-DI among paid workers. Unadjusted mean change from baseline and 95% confidence interval in (a) DAS28-ESR, (b) CDAI, and (c) HAQ-DI. CDAI clinical disease activity index, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire Disability Index, TCZ-SC tocilizumab by subcutaneous injection, W weeks

Back to article page